Sermorelin

At a glance

---

What is sermorelin?

Sermorelin is a synthetic peptide — a chain of 29 amino acids — that is identical to the first 29 amino acids of your body's own growth hormone-releasing hormone (GHRH). This 29-amino-acid fragment is the shortest version that retains the full biological activity of the native 44-amino-acid GHRH molecule.^[1]

GHRH was first isolated in 1982 by two independent research teams led by Roger Guillemin and Wylie Vale. Sermorelin (GRF 1-29) was subsequently developed as the minimal active fragment and eventually became the basis for the FDA-approved drug Geref, which was approved in 1997 for two indications: treating growth hormone deficiency in children, and as a diagnostic test for pituitary GH secretory capacity in adults.

The Geref story matters. In December 2008, EMD Serono voluntarily withdrew Geref from the market — not because of safety concerns, but because recombinant human growth hormone (rhGH) had become the standard of care for pediatric GHD, and sermorelin's market had shrunk. In 2013, the FDA formally confirmed in the Federal Register that the withdrawal was "not for reasons of safety or effectiveness."^[6]

This gives sermorelin the strongest regulatory pedigree of any non-approved GH peptide currently available through compounding pharmacies. It has been through the FDA approval process, has documented safety and efficacy data from that process, and has never been flagged for safety concerns by any regulatory body.

---

How it works

In plain terms, sermorelin tells your pituitary gland to produce and release growth hormone — the same way your brain naturally does. When you inject sermorelin, it binds to the GHRH receptor on pituitary cells and triggers the same signaling cascade that your own GHRH uses.^[5]

The key advantage: because sermorelin works through your body's existing feedback system, the growth hormone release it stimulates is self-limiting. Your brain's built-in brake — a hormone called somatostatin — prevents GH from climbing too high. This is fundamentally different from injecting exogenous growth hormone, which bypasses all feedback regulation and can produce supraphysiological levels.^[4]

Detailed mechanism (for advanced readers)

Sermorelin's mechanism of action is well-characterized:

• Primary target: GHRH receptor (GHRHR) on anterior pituitary somatotroph cells
• Signaling cascade: Binding activates Gs-coupled adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). This drives both GH gene transcription and vesicle exocytosis (immediate GH release).
• Feedback regulation: GH release stimulated by sermorelin is subject to normal negative feedback via somatostatin (from the hypothalamus) and IGF-1 (from the liver). This is the core safety feature — supraphysiological GH levels are self-limiting.
• Pulsatility preservation: Sermorelin preserves the natural pulsatile pattern of GH secretion, unlike exogenous GH injection which creates a flat, non-physiological GH profile.
• Half-life: Approximately 10-20 minutes (very short). This is why bedtime dosing is standard — it aligns the injection with the natural nocturnal GH surge.

How it differs from related compounds:

• vs. CJC-1295: Both are GHRH-pathway compounds, but CJC-1295 has modifications for a much longer half-life (days vs. minutes). CJC-1295 has never been FDA-approved and had a Phase 2 trial terminated after a participant death. Sermorelin has the better regulatory record.
• vs. Ipamorelin: Ipamorelin works on a completely different receptor (GHS-R1a, the ghrelin receptor). Sermorelin and ipamorelin are sometimes combined because they act through complementary pathways — GHRH receptor and ghrelin receptor, respectively.
• vs. Tesamorelin (Egrifta): Tesamorelin is also a GHRH analog but has a trans-3-hexenoic acid modification that extends half-life. It is currently FDA-approved for HIV-associated lipodystrophy.
• vs. Exogenous GH (somatropin): Sermorelin stimulates endogenous production with feedback safety; exogenous GH bypasses all regulation and can cause supraphysiological levels, carpal tunnel syndrome, insulin resistance, and joint pain.

---

What the research says

Sermorelin has the strongest regulatory history of any commonly compounded GH peptide — but its evidence base for adult anti-aging use is limited to small, short-duration trials. The former FDA approval demonstrates safety and GH-stimulating efficacy; what's missing is large-scale proof that those GH elevations translate into meaningful clinical outcomes for adults.

Research timeline

Sermorelin's research history is intertwined with the broader story of growth hormone-releasing hormone:

Human clinical trials

Sermorelin's human evidence base falls into two distinct categories: the FDA approval-era data (pediatric GHD), and a handful of small adult trials for anti-aging applications.

It's worth noting what this evidence doesn't include: no trial has more than 19 participants. No trial lasted longer than 16 weeks. No trial measured hard clinical endpoints like fracture risk, cardiovascular events, or mortality. The adult anti-aging use case rests on GH/IGF-1 elevation (a surrogate endpoint) and self-reported quality of life in very small samples.^[3]

Several additional clinical trials were registered on ClinicalTrials.gov, but none produced substantial results. A University of Washington study on age-related sleep disturbances (NCT00000380) was completed with limited published output. A Johns Hopkins Phase 2 trial in aging adults (NCT00807365) was terminated after the principal investigator left the institution, with only 5 of a planned enrollment actually participating.^[8]

The FDA history

Sermorelin's regulatory journey deserves special attention because it directly informs how we evaluate this peptide today:

1. 1997: FDA approves Geref (sermorelin acetate) for pediatric GHD and as a diagnostic agent. This required submission of preclinical toxicology, clinical efficacy data, and manufacturing standards — the full NDA process.
2. 2008: EMD Serono voluntarily withdraws Geref. Recombinant human GH had become the standard treatment, and sermorelin's market was no longer commercially viable.
3. 2013: In response to a citizen petition, the FDA formally determines that Geref was "not withdrawn from sale for reasons of safety or effectiveness." This is published in the Federal Register on March 4, 2013.^[6]

This last point is crucial. The FDA's 2013 determination means sermorelin's withdrawal carries no safety stigma. It also means the safety and efficacy data from the original NDA remain valid as a regulatory reference.

What sermorelin's compounding position actually rests on

Sermorelin is compounded widely and openly in the United States, and FDA has taken no action against it. Both of those things are verifiable. What we could not verify is the specific legal basis usually given for it — and since that basis is the single most repeated claim about sermorelin, it deserves a straight answer.

Under Section 503A, a bulk drug substance qualifies for compounding by one of three routes:^[13]

1. It is the subject of a USP or NF monograph, or
2. It is a component of an FDA-approved drug product, or
3. It appears on FDA's 503A bulks list.

Sermorelin is not on the 503A bulks list, so route 3 does not apply. An earlier version of this page asserted flatly that sermorelin has "an established USP monograph" — route 1. We could not find one. USP publishes peptide drug-substance monographs for a number of compounds, and sermorelin acetate does not appear among them.

The basis that does hold up is route 2, and it survives the obvious objection. Sermorelin acetate was the active ingredient in Geref, approved under two FDA applications — NDA 019863 and NDA 020443, both held by EMD Serono and both now listed as Discontinued in Drugs@FDA.^[14] The natural worry is that a discontinued product cannot support compounding eligibility. What matters legally is why it was discontinued: FDA maintains a list, at 21 CFR 216.24, of drug products withdrawn or removed from the market because they were found unsafe or ineffective, and products on that list may not be compounded.

We read the full text of that section. Sermorelin and Geref do not appear on it — nor does any growth hormone or somatropin product.^[15] That is consistent with the standard account that Geref was discontinued in 2008 for commercial rather than safety reasons, and it is a checkable fact rather than an industry talking point.

The comparative point stands on its own: sermorelin has never been placed in Category 2, never been nominated and withdrawn, and never been the subject of an FDA safety statement — unlike CJC-1295, ipamorelin, AOD-9604, BPC-157 or TB-500. That difference is real, and it does not depend on the monograph question at all.

---

What the evidence shows

People come to sermorelin with specific goals — usually related to anti-aging, body composition, sleep, or energy. Here's what the published research actually tells us:

---

Safety & side effects

What research shows

Sermorelin has one of the better-documented safety profiles among compounded peptides, thanks to its history as an FDA-approved drug. From the Geref prescribing information and clinical trial data:^[7]

Common side effects (from clinical trials and prescribing data):

• Injection-site reactions: pain, swelling, redness (~16% of patients)
• Headache
• Facial flushing or warmth
• Dizziness or lightheadedness
• Mild nausea (transient)
• Transient fatigue or somnolence

Community-reported side effects

Among people using sermorelin through compounding pharmacies, additional reported effects include:

• Mild water retention
• Joint stiffness (typically at higher doses)
• Generally considered well-tolerated in community reports — fewer complaints than many other peptides in this space

Antibody formation

An important consideration for long-term use: some patients develop anti-sermorelin antibodies with prolonged treatment. In the Geref clinical program, approximately 70% or more of patients developed low-titer antibodies. In most cases, these antibodies do not neutralize the drug's effect. However, in rare cases, high-titer neutralizing antibodies can reduce or eliminate efficacy — a phenomenon called "secondary treatment failure." This is monitored through growth velocity (in children) or IGF-1 levels (in adults).^[1]

Theoretical risks

Contraindications and interactions

Contraindications:

• Active malignancy (GH can stimulate tumor growth)
• Pregnancy and breastfeeding (no safety data for these populations)
• Known hypersensitivity to sermorelin or GHRH analogs
• Obesity may blunt the GH response to sermorelin, potentially limiting efficacy

Drug interactions:

• Glucocorticoids: May blunt the GH response to sermorelin
• Insulin or diabetes medications: GH can reduce insulin sensitivity
• Thyroid medications: GH may alter thyroid hormone metabolism
• Somatostatin analogs (octreotide): Directly antagonize sermorelin's mechanism
• Cyclooxygenase inhibitors (aspirin, indomethacin): May reduce the GH response

---

How people use it

Sermorelin is primarily used by adults seeking to support growth hormone levels as part of an anti-aging or wellness protocol. Here's what the landscape of use looks like.

Administration routes

• Subcutaneous injection (most common): Injected in the abdomen, thigh, or upper arm. Bedtime administration is standard to align with the natural nocturnal GH surge.
• Sublingual/ODT (orally disintegrating tablet): Some compounding pharmacies now offer sublingual forms, though bioavailability data for these routes is limited.

Common stacking context

In clinical and community practice, sermorelin is often discussed alongside other GH-related peptides:

• Sermorelin + Ipamorelin — the most popular combination. Works through complementary pathways (GHRH receptor + ghrelin receptor). No controlled trials of the combination exist.
• Sermorelin + CJC-1295 — redundant in theory (both target the GHRH pathway), though some clinics combine them. Limited rationale from a pharmacological standpoint.
• Sermorelin + GHRP-2 or GHRP-6 — alternative ghrelin receptor agonists sometimes combined with sermorelin.

All combination protocols are based on clinical practice and mechanistic reasoning, not controlled studies.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

---

Legal & regulatory status

As of August 2026:

FDA status

Sermorelin was previously FDA-approved as Geref (1997) for two indications: pediatric growth hormone deficiency and diagnostic evaluation of pituitary GH secretory capacity. It was voluntarily withdrawn by EMD Serono in 2008 for commercial reasons. In March 2013, the FDA formally determined that the withdrawal was NOT for reasons of safety or effectiveness.^[6]

Sermorelin was never placed on the FDA Category 2 list, and — checking FDA's page again in August 2026, content current April 22, 2026 — it does not appear in the "nominated but withdrawn" table either. It appears in neither table. It is compounded under Section 503A with a valid prescription, though the precise statutory route is less settled than commonly presented; see what sermorelin's compounding position actually rests on above.

WADA / USADA status

Sermorelin is prohibited at all times under WADA Section S2, specifically S2.2.4 (growth hormone releasing factors), where the 2026 Prohibited List names sermorelin explicitly alongside CJC-1293, CJC-1295 and tesamorelin. All S2 substances are non-Specified. A Therapeutic Use Exemption is highly unlikely to be approved, as alternative treatments for GH deficiency exist.^[11]

International status

Sermorelin is not currently approved as a treatment drug in any country. The original Geref approval was U.S.-only and has been withdrawn. It is available through compounding pharmacies in the U.S. and through some international clinics.

---

How sermorelin compares

Sermorelin exists in a landscape of GH-related peptides. Here's how it compares to the most commonly discussed alternatives:

The comparison illustrates why sermorelin's regulatory history matters. Both sermorelin and CJC-1295 target the GHRH pathway, but sermorelin has been through the full FDA approval process, had its safety profile documented in prescribing information, and was withdrawn only for commercial reasons. CJC-1295 had a trial participant die during development (attributed to pre-existing coronary artery disease), and the entire clinical program was discontinued.

For someone choosing between GHRH-pathway peptides, sermorelin's regulatory pedigree is a meaningful differentiator — even though both compounds now occupy similar spaces in the compounding market.

---

Common exaggerations to watch for

Sermorelin is sometimes marketed with claims that outrun the evidence. Here are the most common ones to be aware of:

• "FDA-approved for anti-aging" — False. The FDA approvals were for pediatric GHD and diagnostic use, both since withdrawn. Adult wellness use is entirely off-label.
• "Clinically proven to reverse aging" — No sermorelin trial has measured aging biomarkers, lifespan, or healthspan outcomes. The adult trials measured GH/IGF-1 levels and some quality-of-life parameters in very small groups.
• "Guaranteed to increase lean muscle mass" — The Khorram trial showed increased lean body mass in men only, with no significant change in women, in a sample of 19 people over 16 weeks. This is a signal, not a guarantee.
• "Zero side effects" — Sermorelin has documented side effects from its FDA approval era, including injection-site reactions (~16%), headache, and flushing. Antibody formation is also well-documented.
• "Legal to compound because it has a USP monograph" — We could not find a USP-NF monograph for sermorelin acetate, and USP does publish peptide drug-substance monographs for other compounds. The claim appears to be wrong, but the conclusion it supports is not: sermorelin's eligibility rests on having been the active ingredient in Geref, which was discontinued for commercial reasons and does not appear on FDA's withdrawn-for-safety list at 21 CFR 216.24.^[15]

---

Related content

Guide

How to Reconstitute Peptides

A clear, safety-first guide to preparing lyophilized peptides. Essential reading if you're working with sermorelin.

News

FDA Peptide Categories Explained

Sermorelin's Category 1 status and what it means for compounding access.

Tool

Half-Life and Accumulation Plotter

Visualize sermorelin's short half-life and why dosing frequency matters.

---

References

1. [1]

   Prakash A, Goa KL. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs. 1999. 12(2):139-157 DOI PubMedReview

   Comprehensive review covering the Geref approval-era clinical and pharmacological data for sermorelin.

2. [2]

   Vittone J, Blackman MR, Busby-Whitehead J, et al.. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism. 1997. 46(1):89-96 DOI PubMedPilot study

   Open-label, no placebo control. n=11 elderly men. Short duration (6 weeks). Showed GH elevation without IGF-1 increase.

3. [3]

   Khorram O, Laughlin GA, Yen SSC. “Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.” J Clin Endocrinol Metab. 1997. 82(5):1472-1479 DOI PubMedPilot study

   Single-blind, placebo-controlled. n=19 (10 women, 9 men), ages 55-71. 16-week treatment period. Best available adult efficacy data for sermorelin.

4. [4]

   Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?.” Clin Interv Aging. 2006. 1(4):307-308 PubMedReview

   Editorial/review arguing sermorelin preserves more of the GH neuroendocrine axis than exogenous GH. Advocates for sermorelin but acknowledges small study sizes.

5. [5]

   Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Commun. 2020. 3(1):25-37 DOIReview

   Comprehensive review of all GH secretagogues including sermorelin, covering pharmacology and clinical trial history.

6. [6]

   U.S. Food and Drug Administration. “Determination That GEREF (Sermorelin Acetate) Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.” 2013. Link

   Official FDA determination confirming Geref withdrawal was for commercial reasons, not safety. Published March 4, 2013 in the Federal Register.

7. [7]

   EMD Serono (prescribing information, archived). “Geref (Sermorelin Acetate for Injection) — Prescribing Information.” 2002. Link

   Archived prescribing information for FDA-approved Geref. Includes safety data, dosing, contraindications, and antibody formation data from the approval-era clinical program.

8. [8]

   University of Washington. “Sermorelin for age-related sleep disturbances (NCT00000380).” 1996. Link

   Completed trial examining sermorelin for sleep disturbances in aging. Limited published results available.

9. [9]

   Johns Hopkins University. “Sermorelin in aging adults (NCT00807365).” 2007. Link

   Phase 2 trial terminated after PI left the institution. Only 5 participants enrolled. No results published.

10. [10]

    DrugBank. “Sermorelin (DB00010) — DrugBank Entry.” 2025. Link

    Comprehensive pharmacological reference entry for sermorelin including pharmacokinetics, targets, and interactions.

11. [11]

    World Anti-Doping Agency. “The 2026 Prohibited List — International Standard (S2.2.4, growth hormone releasing factors).” 2026. Link

    The 2026 List names sermorelin explicitly in the S2.2.4 bullet for GHRH and its analogues, alongside CJC-1293, CJC-1295 and tesamorelin. Prohibited at all times; non-Specified.

12. [12]

    U.S. Anti-Doping Agency. “Sermorelin athlete guidance.” 2024. Link
13. [13]

    U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” 2026. Link

    FDA's description of the three routes by which a bulk substance may lawfully be used in 503A compounding: a USP or NF monograph, being a component of an FDA-approved drug product, or appearing on the 503A bulks list. Page content current as of May 14, 2026.

14. [14]

    U.S. Food and Drug Administration. “Drugs@FDA: Geref (sermorelin acetate), NDA 019863 and NDA 020443.” 2026. Link

    Queried via the openFDA Drugs@FDA API on August 15, 2026. Confirms two approved applications for sermorelin acetate under the Geref brand, both held by EMD Serono and both with marketing status Discontinued. The site previously cited only NDA 020443.

15. [15]

    U.S. Government Publishing Office. “21 CFR 216.24 — Drug products withdrawn or removed from the market for reasons of safety or effectiveness.” 2024. Link

    Full section text retrieved from GovInfo and read in full on August 15, 2026. Neither sermorelin, Geref, somatropin, nor any growth hormone product appears on the list, which is the operative test for whether a discontinued drug's active ingredient remains eligible for compounding.

16. [16]

    Mendias CL, Awan TM. “Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.” Sports Med. 2026. 56(8):1921-1935 DOI PubMedReview

    2026 review covering sermorelin, ipamorelin, CJC-1295, tesamorelin and AOD-9604. Conclusion: favorable animal data, scarce rigorous human safety data, real potential for serious harm. A review, not new primary data.

---